Biotech


  • Boxes of COVID-19 vaccines from Pfizer and Moderna sit side by side.
    Image attribution tooltip
    Joe Raedle via Getty Images
    Image attribution tooltip

    FDA approves updated COVID boosters, but narrows use

    In a post on X, HHS Secretary Robert F. Kennedy said the FDA has cleared vaccines from Pfizer, Moderna and Novavax for use in "high risk" individuals.

    By Delilah Alvarado • Updated Aug. 27, 2025
  • Psychedelic therapy brain
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    AbbVie dives back into the neuro pool with a $1.2B psychedelics play

    Following a major clinical failure last year, AbbVie’s purchase of a psychedelic depression treatment has the potential to revive a touch-and-go market.

    By Aug. 26, 2025
  • digital pill Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Artificial intelligence & machine learning

    After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

    By PharmaVoice staff
  • FDA
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    Why an FDA decision for a new drug could ripple through the ultra-rare disease space

    All eyes are on Stealth BioTherapeutics as it awaits a long-delayed approval for its first-in-class treatment for Barth syndrome.

    By Alexandra Pecci • Aug. 26, 2025
  • Gilead sign
    Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    And just like that... pharma’s breakups reveal pain points in cancer R&D

    Biotech tie-ups with Gilead, Genetech and Ipsen that have recently been let go.

    By Aug. 22, 2025
  • Frozen pharma vaccine
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A

    In cell therapy, cost is a hot issue. The industry might need a cold solution.

    The logistical linchpin of cryopreservation could make a challenging space more accessible.

    By Aug. 19, 2025
  • Layofdfs
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Biopharma layoffs rise as drugmakers tighten belts and reorganize

    Contrary to a predicted slowdown, 2025’s layoffs are outpacing 2024.

    By Kelly Bilodeau • Aug. 18, 2025
  • Vaccine
    Image attribution tooltip
    Alex Wong via Getty Images
    Image attribution tooltip

    With scrapped mRNA funding, a vaccine maker finds a silver lining

    While mRNA is suffering the brunt of the MAHA movement with $500 million in funding cuts, other vaccine makers could fill some of that void.

    By Aug. 14, 2025
  • Puerto Rico flag
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Puerto Rico’s ongoing journey from manufacturing hub to innovation enterprise

    Biotechs are coming to the island as tariffs threaten overseas drug exports, and finding Puerto Rico is more than just a leading manufacturing hub.  

    By Aug. 12, 2025
  • stem cell treatment
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Are stem cell therapies ready for pharma’s prime time?

    Stem cell therapies are thriving on the fringes of healthcare — but science-backed treatments are also poised to make an impact in pharma R&D.

    By Kelly Bilodeau • Aug. 11, 2025
  • A man in a collared shirt poses for a photograph.
    Image attribution tooltip
    Permission granted by Vertex Pharmaceuticals
    Image attribution tooltip

    David Altshuler, geneticist who helped transform Vertex, to retire next year

    Since becoming Vertex's top scientist in 2015, Altshuler has helped the company become an industry powerhouse. He’ll depart next year in a “planned transition.”

    By Ben Fidler • Aug. 5, 2025
  • Stephane Bancel, Moderna
    Image attribution tooltip
    Chip Somodevilla / Staff via Getty Images
    Image attribution tooltip

    Let’s make a deal? Big Pharma execs express varying views on their M&A future

    Pharma executives are keeping their eyes open for dealmaking opportunities as every company has its own battles to fight.

    By Aug. 5, 2025
  • A smiling portrait of Vinay Prasad, the director of CBER, set against a sparkling light background.
    Image attribution tooltip
    Retrieved from Vinay Prasad on May 08, 2025
    Image attribution tooltip

    Dr. Vinay Prasad, controversial FDA official, abruptly departs agency

    Prasad's exit ends a tumultuous tenure during which he led a reworking of agency guidelines on COVID vaccines and his office got embroiled in controversy over a Duchenne gene therapy.

    By Ben Fidler • July 30, 2025
  • Wall Street
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Biotech investing is down, but some VC firms are bucking the trend

    Discipline is the name of the game after a glut of over-investing burst the biotech bubble.

    By Alexandra Pecci • July 29, 2025
  • Keytruda, Merck
    Image attribution tooltip
    Permission granted by Merck & Co.
    Image attribution tooltip

    Could bispecifics unseat Keytruda from its oncology throne?

    Signals suggest the drugs could improve on the standard of care, but the market may not make it easy for another megablockbuster to rise to the top.

    By Kelly Bilodeau • July 28, 2025
  • Lab bench
    Image attribution tooltip
    E+ via Getty Images
    Image attribution tooltip

    From the bench: Researchers make NIH-funded preclinical strides in mRNA and obesity

    The studies are contributing preclinical advances for some of the world’s biggest blockbusters.

    By July 25, 2025
  • The logo of the Food and Drug Administration is seen in a close-up view of the agency's website.
    Image attribution tooltip
    Mario Guti via Getty Images
    Image attribution tooltip

    Who is Dr. George Tidmarsh, the new director of CDER?

    Despite past criticism of public health policies, Tidmarsh recently praised the FDA and said he’ll focus on boosting review efficiencies.

    By Meagan Parrish and Michael Gibney • July 23, 2025
  • Chinese flag with lot of medical pills isolated on black background
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    FDA invites more data from abroad — with a wary eye on China

    The FDA approved four drugs last year without any U.S. trial participants, but has maintained a tougher stance on China, even as it grows into an R&D powerhouse.

    By July 16, 2025
  • stock numbers below a NYSE sign
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip

    Biotech IPO momentum gained steam last year, but market ‘turmoil’ has slowed the train again

    The IPO market is a mixed bag in 2025, with some signs of life but several headwinds keeping activity relatively low.

    By July 15, 2025
  • measles texas
    Image attribution tooltip
    Jan Sonnenmair via Getty Images
    Image attribution tooltip

    Early measles drug R&D kicks into gear as U.S. records record outbreak

    Several companies have announced preclinical efforts to develop the first-ever measles treatment.

    By July 11, 2025
  • Laboratory bottles with blue content and a syringe
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    First 90 Days

    As its cancer vaccine moves through the clinic, Transgene sets sights on manufacturing

    Simone Steiner recently joined the French company to set the stage for launch.  

    By July 9, 2025
  • Button
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Is biopharma dealmaking getting hot again?

    With pharma’s finger on the M&A button, three of the biggest deals of the year are breadcrumbs that could lead to a full-on resurgence.

    By July 8, 2025
  • Intravenous drip of medicine at the hospital
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The MEK effect on cancer — a slow and steady approach to drug resistance

    Immuneering Corporation’s investigational MEK inhibitor aims to outpace cancer while reducing resistance and side effects.

    By Kelly Bilodeau • July 8, 2025
  • China flag
    Image attribution tooltip
    E+ via Getty Images
    Image attribution tooltip

    Can China sustain a surge in oncology drug innovation?

    The country’s trajectory may get a boost from anticipated results of a Keytruda rival’s U.S. trials.

    By Kelly Bilodeau • July 2, 2025
  • AI brain
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    AI’s ‘massive transition’ in biopharma shapes leadership mindsets — tension and all

    The AI revolution is driving tension between new technology and the traditional approaches in drugmaking. Biopharma leaders are trying to navigate those turbulent waters.

    By July 1, 2025
  • A person in a business suit looks past two other people standing with their backs to the camera.
    Image attribution tooltip
    Elijah Nouvelage via Getty Images
    Image attribution tooltip

    CDC panel, newly remade by RFK Jr., questions vaccine evidence

    New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at other established shots, like those for measles and hepatitis B.

    By Delilah Alvarado • June 26, 2025